Table 3 Clinical trials of HER2-targeted bispecific antibodies
Drug | Targets | Diseases | Treatment arms | Phase | Status | Identifier |
|---|---|---|---|---|---|---|
Ertumaxomab | HER2/CD3 | Metastatic breast cancer | Ertumaxomab | 2 | Terminated | NCT00452140 |
Ertumaxomab | HER2/CD3 | Metastatic breast cancer | Ertumaxomab | 2 | Terminated | NCT00522457 |
Ertumaxomab | HER2/CD3 | Her2+ advanced solid tumors | Ertumaxomab | 1/2 | Terminated | NCT01569412 |
MM-111 | HER2/HER3 | Her2+, heregulin+, breast cancer | MM-111 | 1 | Completed | NCT00911898 |
MM-111 | HER2/HER3 | Her2+, heregulin+, breast cancer | MM-111Â +Â trastuzumab | 1 | Completed | NCT01097460 |
MM-111 | HER2/HER3 | HER2+ solid tumors | a. Cisplatin + capecitabin + trastuzumab + MM-111 b. Lapatinib ± trastuzumab + MM-111 c. Paclitaxel + trastuzumab + MM-111 d. Lapatinib + trastuzumab + paclitaxel + MM-111 e. Docetaxel + trastuzumab + MM-111 | 1 | Completed | NCT01304784 |
MM-111 | HER2/HER3 | HER2+ esophagus cancer, gastroesophageal junction cancer, stomach cancer | a. MM-111 + paclitaxel + trastuzumab b. Paclitaxel + trastuzumab | 2 | Completed | NCT01774851 |
HER2Bi-aATC | HER2/CD3 | Her2+ neoplasms of digestive system | Interleukin-2Â +Â HER2Bi-aATC | 1 | Recruiting | NCT02662348 |
MCLA-128 | HER2/HER3 | HER2+ malignant solid tumors | a. MCLA-128 dose escalation b. MCLA-128 for breast cancer c. MCLA-128 for ovarian cancer d. MCLA-128 for gastric/GE junction cancer e. MCLA-128 for endometrial cancer f. MCLA-128 for NSCLC | 1/2 | Recruiting | NCT02912949 |
GBR1302 | HER2/CD3 | HER2+ solid tumors | GBR1302 | 1 | Recruiting | NCT02829372 |
ZW25 | Two different epitopes of HER2 | HER2+ solid tumors | ZW25 | 1 | Recruiting | NCT02892123 |